Verteporfin

製品コードS1786 別名:CL 318952

Verteporfin 化学構造

分子量(MW):718.79

Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin.

サイズ 価格(税別)  
JPY 53120.00
JPY 161020.00

カスタマーフィードバック(3)

  • Verteporfin treatment inhibits proliferation and induces apoptosis of Tsc1-null cells in vivo. Mice were administered i.p. with vehicle or verteporfin at a dose of 100 mg/kg every other day for 10 d before sacrifice. Mice were sacrificed at 6 wk of age. Three independent experiments were performed and mice in different treatments were pooled for analysis. Percentage of Ki67 and αSMA double-positive cells in α-SMA+ mesenchymal lesions in the indicated kidneys. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse.

    J Exp Med 2014 211(11), 2249-63. Verteporfin purchased from Selleck.

    The indicated cell lines were treated with control (Ctrl) or YAP-targeting siRNAs and growth assessed by XTT proliferation assays at the indicated time points. The mean and +SD are shown for three independent experiments. (Left panel, *, P < 0.05, significantly different from U87Rictor DMSO; Right panel, *, P < 0.05, significantly different from H4Rictor DMSO).

    J Biol Chem, 2015, 290(32): 19387-401 . Verteporfin purchased from Selleck.

  • The levels of YAP, phospho-YAP (S127), and its downstream targeted molecules CTGF and CYR61 were analyzed by Western blotting after UM cells were exposed to verteporfin for 24 hours.

    Am J Cancer Res, 2016, 6(12):2816-2830.. Verteporfin purchased from Selleck.

製品安全説明書

VDA阻害剤の選択性比較

生物活性

製品説明 Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin.
ターゲット
VDA [1]
(Endothelial cells)
YAP/TEAD interaction [3]
体外試験

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. [1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL-60 NVPVcXpmTnWwY4Tpc44h[XO|YYm= M4O4OZ4yODBibnevcWw> M3fsUWROW09? M{j1Solv[3KnYYPld{BFVkFiZoLh[41mdnSjdHnvckBt\X[nbIO= M4PFTVExPjB5N{Gw
HL-60 NWjnTGdT[3m2b4TvfIlkcXS7IHHzd4F6 MYT+NVAxKG6pL33M MX3EUXNQ NIHNSlRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NX;aUXVOOTB4MEe3NVA>
Jurkat NIHSXJJCeG:ydH;zbZMh[XO|YYm= NVPIZnQ6hjJ6MDDuUS=> NILYNFdFVVOR Mm\2bY5lfWOnczDhJGJkdC1{LXTldIVv\GWwdDDhdI9xfG:|aYO= MXWxNVI1PTRzNR?=
RIF-1 MUfGeY5kfGmxbjDhd5NigQ>? M1rKO|Eh|rypL33s NVTsNJRFTE2VTx?= M2DwNoRm[3KnYYPld{BwgHmpZX6gZ49ve3WvcITpc44> NIXZUm0yOjZzNUexPC=>
RIF-1 M1fCWoN6fG:2b4jpZ4l1gSCjc4PhfS=> NHe5SoUyKM7:Zz;tcC=> M3THWGROW09? M4SxR4Rm[3KnYYPlJJRwKDJyINMxJFUmKGOnbHygd5Vzfmm4YXy= MorINVI3OTV5MUi=
SVEC4-10 MoPGSpVv[3Srb36gZZN{[Xl? NHnaOZYzODBibnevcYw> M17tTWROW09? NH\iZ5FqdmS3Y3XzJI1q[3KxdIXieYxmKGSncH;sfY1memm8YYTpc44> M1zCeVE3PDZ5MUC2
SVEC4-10 MUnGeY5kfGmxbjDhd5NigQ>? NUHQdVY1OjByIH7nM41t M4r3RWROW09? NWW1UI4{cW6mdXPld{B{fHKnc4OgZYN1cW5iZnni[ZIh\m:{bXH0bY9v NYjvNWNEOTZ2NkexNFY>
ARPE-19 NG\aRXNkgXSxdH;4bYNqfHliYYPzZZk> NWfLU4JJhjBwMTFOwIcwdWx? NEfWVZVFVVOR M33NcpNpd3e|IHGg[I9{\S2mZYDlcoRmdnRidH;4bYNqfHl? MmPiNVY6QDd7MEW=
ARPE-19 NWPCfINNTnWwY4Tpc44h[XO|YYm= MnnDNE4xOSEQvHevcYw> NUTaPFBOTE2VTx?= M2G2Zolv[3KnYYPld{BXTUeIIHHu[EBz\WS3Y3XzJHBGTEZiZYjwdoV{e2mxbh?= MnLRNVY6QDd7MEW=
Y-79 MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3HLbp4yKM7:Zz;tcC=> NUDvN4NLTE2VTx?= NVP6dWhx\GWlcnXhd4V{KHKndHnuc4Jt[XO2b33hJINmdGxicILvcIln\XKjdHnvci=> NYPVfm91OTh3N{m3OlQ>
WERI-Rb1 NFPzO5JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYX+NUDPxGdxbXy= NWj0SnVTTE2VTx?= Ml20[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= NHfyd24yQDV5OUe2OC=>
RB247C3 NH3w[npIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3jSPZ4yKM7:Zz;tcC=> MoO4SG1UVw>? Mlrq[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= MljFNVg2Pzl5NkS=
RB355 NEW0SZFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoXCglEh|rypL33s MV7EUXNQ NVPIVY5s\GWlcnXhd4V{KHKndHnuc4Jt[XO2b33hJINmdGxicILvcIln\XKjdHnvci=> NHz6eXoyQDV5OUe2OC=>
RB383 M{nTcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1nrZ54yKM7:Zz;tcC=> MWrEUXNQ NEDDXIJl\WO{ZXHz[ZMhemW2aX7vZoxie3SxbXGgZ4VtdCCycn;sbYZmemG2aX;u MV2xPFU4QTd4NB?=
hFibro NVv2SXRy[3m2b4TvfIlkcXS7IHHzd4F6 NWGxbGU{OC53INM1[{9udA>? MljoSG1UVw>? NYDYZlR6\GWlcnXhd4V{KH[rYXLpcIl1gSCkeTC4Okw2LQ>? MU[yN|Q1OTFzNB?=
pTMC M3;m[YN6fG:2b4jpZ4l1gSCjc4PhfS=> NWeyS2V7OC53INM1[{9udA>? NG\IdIhFVVOR M{XqZoRm[3KnYYPld{B3cWGkaXzpeJkh[nliOUKuPUU> NEPNdm0zOzR2MUGxOC=>
hTMC NGT4NGJkgXSxdH;4bYNqfHliYYPzZZk> NIfaeHYxNjViwsXnM41t MkG2SG1UVw>? MlfB[IVkemWjc3XzJJZq[WKrbHn0fUBjgSB6OD65KS=> MorONlM1PDFzMUS=
ARPE-19 MWHjfZRwfG:6aXPpeJkh[XO|YYm= NFHtfmIxNjViwsXnM41t NVnheZY{TE2VTx?= M1rLSoRm[3KnYYPld{B3cWGkaXzpeJkh[nliNUWuOUU> NXrNZ3E{OjN2NEGxNVQ>
Panc-1 MnrrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkC2NVAh|ryP M1HaWGROW09? MlrabY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NF;GTnozPDB4OUC2PS=>
MIA PaCa-2 M3q4cGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWrMUYlLOTBizszN NVfIeZJ5TE2VTx?= M37abYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> MlvPNlQxPjlyNkm=
BxPC-3 MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1G1cVExKM7:TR?= MmLDSG1UVw>? MV3pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfS=> MVeyOFA3QTB4OR?=
SU86.86 NUDBTVBqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFfuPGoyOCEQvF2= MXXEUXNQ MkPXbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJk> MmDGNlQxPjlyNkm=
MCF-7 M{fwNWF2fG:yaHHnfUBie3OjeR?= NF33O4UyOCEQvF2= MoC3SG1UVw>? MlnTbY5pcWKrdIOg[4Vu[2m2YXLpcoUucW6mdXPl[EBifXSxcHjh[5k> NGfsVFIzPDB4OUC2PS=>
WERI M1G1[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWr+NVAh|rypL33s M2\QdmROW09? NWS2fphTcW6qaXLpeJMh\3Kxd4ToJI9nKHKndHnuc4Jt[XO2b33hJINmdGy| Ml7NNlQ5OzdzNEK=
WERI MmnTSpVv[3Srb36gZZN{[Xl? M3P3fp4yOCEQvHevcYw> MVvEUXNQ MYficI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvci=> MV:yOFg{PzF2Mh?=
Y-79 M3u5UGZ2dmO2aX;uJIF{e2G7 NFTOXHh,OTBizsznM41t NIDHVmNFVVOR MVficI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvci=> NVnqeItkOjR6M{exOFI>
Y-79 NV7NSYpYTnWwY4Tpc44h[XO|YYm= M{XHdp4yOCEQvHevcYw> M13vcmROW09? M3rmfIFn\mWldIOgXWFRNVSHQVSgdJJwfG9vb37jc4dmdmVicHH0bJdigQ>? M{T4cVI1QDN5MUSy
Y-79 MmXQSpVv[3Srb36gZZN{[Xl? M4fPV54yOCEQvHevcYw> NXfyb4xwTE2VTx?= NEfLb25ld3ewLYLl[5Vt[XSnczDwcJVzcXCxdHXuZ5khdWG{a3XyJG9EXC12 NF;HeHozPDh|N{G0Ni=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. [1]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (139.12 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 718.79
化学式

C41H42N4O8

CAS No. 129497-78-5
保管
in solvent
別名 CL 318952

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03067051 Recruiting Recurrent Prostate Cancer SpectraCure AB March 21 2017 Phase 1
NCT03033225 Recruiting Pancreatic Cancer Non-Resectable Mayo Clinic January 5 2017 Phase 2
NCT02939274 Recruiting Metastatic Breast Cancer Rogers Sciences Inc. October 2016 Phase 2
NCT02702700 Recruiting Pleural Effusion Malignant Centre Hospitalier Universitaire Vaudois January 2016 Phase 1
NCT02495181 Recruiting Polypoidal Choroidal Vasculopathy Association for Innovation and Biomedical Research on Light and Image|European Vision Institute Clinical Research Network January 2016 Phase 4
NCT02457026 Withdrawn Neovascular Age-related Macular Degeneration Duke University|Bausch & Lomb Incorporated January 2016 Not Applicable

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

VDAシグナル伝達経路

相関VDA製品

Tags: Verteporfin を買う | Verteporfin ic50 | Verteporfin 供給者 | Verteporfin を購入する | Verteporfin 費用 | Verteporfin 生産者 | オーダーVerteporfin | Verteporfin 化学構造 | Verteporfin 分子量 | Verteporfin 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID